Given the suppressive effect of miR-155 on PD-L1 expression (7,8), there is an anticipated negative impact of anti-miR-155 on anti-cancer immunity through enhanced expression of the immune checkpoint programmed death ligand 1 (PD-L1). This evidence concerns the gene CD274 and cancer.